Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the effectiveness and safety of zanidatamab combined with a physicians choice of chemotherapy compared to trastuzumab combined with chemotherapy in treating adults with metastatic HER2-positive breast cancer who have either progressed on or cannot tolerate previous trastuzumab deruxtecan T-DXd treatment. Zanidatamab has shown promising results against various HER2-positive advanced tumors, including metastatic breast cancer, and may serve as a potential treatment option for these patients. The study also investigates patient-reported tolerability and physical functioning, as well as the pharmacokinetics and immune response to zanidatamab with chemotherapy. Participants will be randomly assigned to receive either zanidatamab or trastuzumab, each given by intravenous infusion alongside one of several chemotherapy options chosen by the physician eribulin, vinorelbine, gemcitabine, or capecitabine the latter is taken orally. Treatment will be administered according to the assigned group, and the study is open-label and multicenter, designed to compare these two treatment combinations in this patient population. During the study, participants will undergo regular assessments to monitor disease progression using imaging criteria RECIST version 1.1, evaluate survival, treatment response, and duration of response. Safety and side effects will be tracked through adverse event reporting and patient questionnaires on symptoms and physical function. Blood samples will be collected to study drug levels and immune reactions. Participants will be followed until disease progression, death, or for up to approximately 44 months for key outcomes, with overall survival monitored for up to about 80 months.
Actively Recruiting
Researchers are evaluating the safety, pharmacokinetics, and early activity of GDC-7035, both alone and combined with other anti-cancer therapies, in adults with advanced or metastatic solid tumors that have the KRAS G12D mutation. This first-in-human Phase III study is open-label and conducted at multiple centers, focusing on patients with this specific genetic tumor marker. Participants receive GDC-7035 in two study arms one with GDC-7035 alone and the other with GDC-7035 combined with other anti-cancer treatments. The study involves dose escalation and expansion phases with protocol-defined dosing to determine safe and effective dose levels. During the trial, participants are closely monitored for side effects, dose-limiting toxicities, and blood levels of the drug at specified times. Researchers measure response rates, duration of response, and progression-free survival over a period of up to four years. The study involves regular evaluations to assess safety and drug activity throughout the treatment period.
Actively Recruiting
Researchers are evaluating the efficacy and safety of ifinatamab deruxtecan I-DXd in adults with various recurrent or metastatic solid tumors, including endometrial cancer, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer, hepatocellular carcinoma, adenocarcinoma of the esophagus and stomach, urothelial carcinoma, ovarian cancer, cervical cancer, biliary tract cancer, HER2-low and HER2 IHC 0 breast cancer, cutaneous melanoma, and neuroendocrine carcinoma. The study is an open-label, phase 1B2 trial with multiple cohorts and includes a safety run-in phase for hepatocellular carcinoma participants. Participants receive I-DXd through intravenous infusions at a dose of 12 mgkg with a determined dose for hepatocellular carcinoma in repeated cycles. The trial is divided into three parts Stage 1, Stage 2, and an optional Stage 3 for the endometrial cancer cohort based on safety and efficacy data. Each cohort starts with Stage 1 and may progress to Stage 2 if criteria are met. The hepatocellular carcinoma cohort undergoes a safety run-in phase to assess tolerability. During the trial, participants will have tumor samples collected before treatment, imaging assessments to measure disease response, and regular monitoring for side effects and adverse events. Researchers will evaluate objective response rate, dose-limiting toxicities, treatment-emergent adverse events, duration of response, progression-free survival, disease control rate, overall survival, pharmacokinetics, and immune responses over a period of up to approximately 60 months. Participants will be followed closely through scheduled visits and tests throughout the study duration.